Fiocruz extends international cooperation agreement with ECLAC

19 June 2023
fiocruz_brazil_large

Brazil’s scientific institution for R&D, Fiocruz, has signed a memorandum of understanding (MoU) that extends international cooperation with the Economic Commission for Latin America and the Caribbean (ECLAC).

Signed by the Vice President of Education, Information and Communication (VPEIC), Cristiani Machado, and by the Executive Secretary of ECLAC, José Manuel Salazar-Xirinachs, the document extends the partnership for another five years, with three central axes: monitoring the 2030 Agenda and its interface between health and the Sustainable Development Goals (SDGs); strategic prospecting; and support for local production to increase the region's capacity to respond to health emergencies.

With the signing, a period of six months was established for the development of a work plan that unfolds these three axes in concrete actions involving not only the Fiocruz Strategy for the 2030 Agenda (EFA 2030) and the Center for Strategic Studies (CEE), involved since the first signing in 2018, but also the other units of the Foundation. The idea is that Fiocruz's experience can be shared with other countries, improving the quality of health and strengthening the production capacity of drugs, tests and vaccines, aiming at the autonomy of the region.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical